Neurocritical Care News

A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

Concussions suffered in hockey led to substantial missed playing time, while their physical effects require leagues of all ages to bolster rules, utilize protective equipment and implement high-quality injury protocols to address the issue.

Published results showed gender may not be a significant factor in return to learn rates for high school athletes with sports-related concussions.

Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.

Published results showed an investigational head and neck cooling device reduced symptom severity for adolescent athletes with a sports-related concussion compared with standard post-concussion care alone.

NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.

Certain physical exercises may prevent nerve damage caused by chemotherapy among individuals being treated for cancer, results of a randomized study published in JAMA Internal Medicine showed.

Implementation of tissue bridges measured within the first weeks after spinal cord injury are linked with short-and-long-term clinical improvement, according to research from The Lancet Neurology.

Avidity Biosciences Inc. has announced positive data from the phase 1/2 FORTITUDE clinical trial of a proprietary monoclonal antibody that binds to the transferrin receptor 1 conjugated with a siRNA targeting DUX4 mRNA.